Resolutions from the Extraordinary General Meeting in Peptonic Medical
Stockholm, July 22, 2016. Peptonic Medical AB (publ) – a company developing pharmaceuticals based on oxytocin – today announced that an extraordinary general meeting was held on the 22nd July 2016.
The extraordinary general meeting resolved, in accordance with the Board’s proposal, to elect Mr Arne Ferstad as a new non-executive member of Peptonic Medical’s Board of Directors. Prof. Emeritus Andris Kreichbergs resigned from the Board for personal reasons as previously announced.
For further information, please contact:
Johan Inborr, CEO
Phone: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
About Arne Ferstad
Arne Ferstad has broad experience of the medical device, biotech and pharmaceutical industries, including General Management, R&D, Business Development and International Marketing and Sales. He has been in charge of Baxter Healthcare’s business in the Nordic and Benelux countries, served as President of EMEA Baxter Renal Division, managed Baxter’s bioscience business in Asia and has held several senior positions within Baxter Healthcare Inc. in the USA. He has also worked as Subsidiary CEO/General Manager and VP at Pharmacia Corporation. Arne Ferstad is presently Chairman and CEO of Ankor Consultants Ltd, where he works with clients as consultant, as interim executive and non-executive board member of several companies. Education in finance, marketing and completed the CEDEP, Executive Management Program at INSEAD Cedep, France.
Other current assignments: CEO and chair of Ankor Consultants Ltd (United Kingdom), Board member and Chairman of the board in Aggancio Research AB and CombiGene AB. Board member of NeuroVive Pharmaceutical AB, Clinical Laserthermia Systems AB and C G VET AB
About Peptonic Medical
Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Peptonic Medical’s mission is to develop safe and effective drugs based on the well-known beneficial properties of oxytocin.